Trending

U.S FDA clears OBI Pharma's investigational new drug (IND) application for a Phase 1 study of a monoclonal antibody cancer immunotherapy targeting Globo H, a glycolipid antigen…
Read More...

BioLineRx, committed to oncology and immunology declared partial results from the monotherapy portion of BL-8040's Phase 2a COMBAT study. The study reveals that BL-8040 increases…
Read More...

MiMedx Group confirmed the enrollment of first patients in the Company's Phase 3 Investigational New Drug (IND) Clinical Trial for MiMedx's micronized amniotic tissue, AmnioFix…
Read More...

GC Pharma, a South Korean biopharmaceutical company affirmed that it will conduct Phase 2/3 clinical trial for GC1102, the company's investigational recombinant hepatitis B immune…
Read More...

In a bid to ensure transparency and clarity in their drug approval decisions,  U.S FDA Commissioner Scott Gottlieb endeavors to undertake new drug innovation and Scientific progress by…
Read More...

Ophthalmic Pharmaceutical Company, Aerie Pharmaceuticals that seeks to treat patients with open-angle glaucoma and other diseases of the eye declared the appointment of Nils Hauptmann…
Read More...

Ophthotech Corporation enrolled first patient in the Phase 2b randomized, double-masked, sham-controlled clinical trial assessing the efficacy and safety of Zimura complement C5…
Read More...

Developer of surgical implants for treating distal extremity pathology, Centric Medical asserted that the U.S FDA has granted 510 (k) clearance to the Cannulated Screw Internal Fixation…
Read More...

Sarah Cannon Research Institute and South Texas Research Accelerated Therapeutics moved to collaborate ensuring augmenting their globally acclaimed phase I drug development programs…
Read More...

Ipsen and Exelixis declared results of Phase 3 CELESTIAL trial in  patients formerly treated with advanced heptacellular carcinoma. In CELESTIAL, cabozantinib provided a statistically…
Read More...

Antibody discovery and optimization service provider, AvantGen claimed completion of its first cancer therapeutic antibody program in collaboration with Tanabe Research Laboratories USA…
Read More...

Cytovance Biologics a biopharmaceutical contract manufacturer of mammalian and microbial biologics proclaimed Edwin Miranda as Vice-President of Quality. Dr. Jesse McCool, Sr. Vice…
Read More...

Lustgarten Foundation alleges $22 million funding in 2017 as part of its mission to invest an unprecedented $40 million by the end of 2018. In a bid to advanced pancreatic Cancer…
Read More...

CGMP contract development and manufacturing organization (CDMO), Nitto Avecia Pharma Services appointed Raymond Kaczmarek as the president entrusting the P&L responsibility for the…
Read More...

Diplomat Pharmacy mets out CABOMETYX treatment for Renal cell carcinoma inflicted on patients as approved by the Food and Drug administration. Formerly approved as a second-line therapy…
Read More...

BD (Becton, Dickinson and Company), global medical technology company, along with Check-Points Health B.V., affirmed that the companies sought CE Mark for a next-generation molecular…
Read More...

Labeling and detection solutions, Bio-Techne now provides reagents and kits from Vector Laboratories that doles out reliable, sensitive, and low background detection. In October, 2017,…
Read More...

Genomic and Medical research knowledge base powered by the blockchain and owned by its community, Luna DNA declared Dawn Barry as president. Barry will be held accountable for leading…
Read More...

U.S Stem Cell, Inc. claimed to be a leader in the development of proprietary stem cell therapies asserted accomplishing the target of 10,000 kit sales of proprietary Adipocell product,…
Read More...

U.S FDA approves Teva Pharmaceutical's TRISENOX i.e. Arsenic trioxide injection amalgamated with  tretinoin  in the therapy of adults diagnosed with low -risk acute promyelocytic…
Read More...